STOCK TITAN

[8-K] Spirit Aerosystems Holdings, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

IDEAYA Biosciences (IDYA) filed a Form S-8 on 5 Aug 2025 to register 2,000,000 additional common shares for issuance under its 2023 Employment Inducement Award Plan, raising the total shares registered for the plan to 4 million. The plan, adopted and amended by the board under Nasdaq Rule 5635(c)(4) without shareholder approval, is intended to grant equity awards to new hires. The filing incorporates by reference the company’s 2024 Form 10-K, 2025 Form 10-Qs and recent 8-Ks, and includes customary legal opinions and consents. No financial performance data or changes to corporate strategy are disclosed; the action is administrative and may cause modest dilution if all shares are issued.

IDEAYA Biosciences (IDYA) ha depositato un modulo S-8 il 5 agosto 2025 per registrare 2.000.000 di azioni ordinarie aggiuntive da emettere nell'ambito del suo Piano di Incentivi Occupazionali 2023, portando il totale delle azioni registrate per il piano a 4 milioni. Il piano, adottato e modificato dal consiglio di amministrazione secondo la Regola Nasdaq 5635(c)(4) senza l'approvazione degli azionisti, è destinato a concedere premi azionari ai nuovi assunti. Il deposito fa riferimento al modulo 10-K 2024, ai moduli 10-Q 2025 e agli ultimi 8-K della società, includendo le consuete opinioni legali e consensi. Non vengono divulgati dati finanziari o cambiamenti nella strategia aziendale; l'operazione è di natura amministrativa e potrebbe causare una diluizione modesta se tutte le azioni verranno emesse.

IDEAYA Biosciences (IDYA) presentó un Formulario S-8 el 5 de agosto de 2025 para registrar 2,000,000 acciones ordinarias adicionales para emisión bajo su Plan de Premios por Inducción Laboral 2023, elevando el total de acciones registradas para el plan a 4 millones. El plan, adoptado y modificado por la junta bajo la Regla Nasdaq 5635(c)(4) sin aprobación de los accionistas, está destinado a otorgar premios en acciones a los nuevos empleados. La presentación incorpora por referencia el Formulario 10-K 2024, los Formularios 10-Q 2025 y los recientes 8-K de la compañía, e incluye opiniones legales y consentimientos habituales. No se divulgan datos financieros ni cambios en la estrategia corporativa; la acción es administrativa y podría causar una dilución modesta si se emiten todas las acciones.

IDEAYA Biosciences (IDYA)는 2025년 8월 5일에 2023년 고용 유인 보상 계획 하에 발행할 추가 보통주 2,000,000주를 등록하기 위해 Form S-8을 제출했으며, 이로써 해당 계획에 등록된 총 주식 수는 400만 주로 증가했습니다. 이 계획은 Nasdaq 규칙 5635(c)(4)에 따라 이사회가 주주 승인 없이 채택 및 수정했으며, 신입 사원에게 주식 보상을 부여하는 것을 목적으로 합니다. 제출 서류에는 회사의 2024년 Form 10-K, 2025년 Form 10-Q 및 최근 8-K가 참조로 포함되어 있으며, 일반적인 법률 의견서와 동의서도 포함되어 있습니다. 재무 성과 데이터나 기업 전략 변경 사항은 공개되지 않았으며, 이번 조치는 행정적 성격으로 모든 주식이 발행될 경우 소폭의 희석 효과가 발생할 수 있습니다.

IDEAYA Biosciences (IDYA) a déposé un formulaire S-8 le 5 août 2025 pour enregistrer 2 000 000 d'actions ordinaires supplémentaires à émettre dans le cadre de son Plan de Récompenses d'Embauche 2023, portant le total des actions enregistrées pour ce plan à 4 millions. Ce plan, adopté et modifié par le conseil d'administration conformément à la règle Nasdaq 5635(c)(4) sans approbation des actionnaires, vise à attribuer des actions aux nouveaux employés. Le dépôt incorpore par référence le formulaire 10-K 2024, les formulaires 10-Q 2025 et les récents 8-K de la société, incluant les avis juridiques habituels et les consentements. Aucune donnée financière ni changement de stratégie d'entreprise n'est divulgué ; cette action est de nature administrative et pourrait entraîner une dilution modérée si toutes les actions sont émises.

IDEAYA Biosciences (IDYA) reichte am 5. August 2025 ein Formular S-8 ein, um zusätzlich 2.000.000 Stammaktien zur Ausgabe im Rahmen seines Employment Inducement Award Plans 2023 zu registrieren, wodurch die insgesamt für den Plan registrierten Aktien auf 4 Millionen steigen. Der Plan, der vom Vorstand gemäß Nasdaq-Regel 5635(c)(4) ohne Zustimmung der Aktionäre angenommen und geändert wurde, soll Aktienprämien an Neueinstellungen gewähren. Die Einreichung bezieht sich auf den 2024er Form 10-K, die 2025er Form 10-Qs und die aktuellen 8-Ks des Unternehmens und enthält die üblichen rechtlichen Gutachten und Zustimmungen. Es werden keine finanziellen Leistungsdaten oder Änderungen der Unternehmensstrategie offengelegt; die Maßnahme ist administrativ und kann bei vollständiger Ausgabe aller Aktien zu einer moderaten Verwässerung führen.

Positive
  • Enhanced hiring flexibility: additional shares strengthen IDYA’s ability to attract and retain specialized biotech talent through equity incentives.
Negative
  • Potential dilution: up to 2 million new shares could marginally dilute existing shareholders when issued.

Insights

TL;DR – Routine S-8 adds 2 M shares for employee grants; minor dilution, neutral fundamental impact.

The registration simply increases the share pool available for inducement awards, bringing total potential issuance under this plan to roughly 4 % of IDYA’s 50 M outstanding shares (estimate based only on filing data). Such filings are common for high-growth biotech firms competing for talent. While the issuance could incrementally dilute existing holders once granted and vested, the move does not alter cash flows, debt, or near-term guidance. Given the absence of financial metrics or strategic shifts, I view the capital-markets impact as neutral.

TL;DR – Board-only adoption under Nasdaq 5635(c)(4) limits shareholder voice; standard but worth monitoring.

Use of the inducement exemption allows equity awards without shareholder approval, speeding recruitment but bypassing investor oversight of dilution limits. Exhibits show plan amendments on 25 Jun 2024 and 21 May 2025, suggesting iterative expansion. Governance risk is modest provided disclosures remain transparent and grants stay within market norms. Overall, the filing is not materially impactful yet signals a continued reliance on equity compensation.

IDEAYA Biosciences (IDYA) ha depositato un modulo S-8 il 5 agosto 2025 per registrare 2.000.000 di azioni ordinarie aggiuntive da emettere nell'ambito del suo Piano di Incentivi Occupazionali 2023, portando il totale delle azioni registrate per il piano a 4 milioni. Il piano, adottato e modificato dal consiglio di amministrazione secondo la Regola Nasdaq 5635(c)(4) senza l'approvazione degli azionisti, è destinato a concedere premi azionari ai nuovi assunti. Il deposito fa riferimento al modulo 10-K 2024, ai moduli 10-Q 2025 e agli ultimi 8-K della società, includendo le consuete opinioni legali e consensi. Non vengono divulgati dati finanziari o cambiamenti nella strategia aziendale; l'operazione è di natura amministrativa e potrebbe causare una diluizione modesta se tutte le azioni verranno emesse.

IDEAYA Biosciences (IDYA) presentó un Formulario S-8 el 5 de agosto de 2025 para registrar 2,000,000 acciones ordinarias adicionales para emisión bajo su Plan de Premios por Inducción Laboral 2023, elevando el total de acciones registradas para el plan a 4 millones. El plan, adoptado y modificado por la junta bajo la Regla Nasdaq 5635(c)(4) sin aprobación de los accionistas, está destinado a otorgar premios en acciones a los nuevos empleados. La presentación incorpora por referencia el Formulario 10-K 2024, los Formularios 10-Q 2025 y los recientes 8-K de la compañía, e incluye opiniones legales y consentimientos habituales. No se divulgan datos financieros ni cambios en la estrategia corporativa; la acción es administrativa y podría causar una dilución modesta si se emiten todas las acciones.

IDEAYA Biosciences (IDYA)는 2025년 8월 5일에 2023년 고용 유인 보상 계획 하에 발행할 추가 보통주 2,000,000주를 등록하기 위해 Form S-8을 제출했으며, 이로써 해당 계획에 등록된 총 주식 수는 400만 주로 증가했습니다. 이 계획은 Nasdaq 규칙 5635(c)(4)에 따라 이사회가 주주 승인 없이 채택 및 수정했으며, 신입 사원에게 주식 보상을 부여하는 것을 목적으로 합니다. 제출 서류에는 회사의 2024년 Form 10-K, 2025년 Form 10-Q 및 최근 8-K가 참조로 포함되어 있으며, 일반적인 법률 의견서와 동의서도 포함되어 있습니다. 재무 성과 데이터나 기업 전략 변경 사항은 공개되지 않았으며, 이번 조치는 행정적 성격으로 모든 주식이 발행될 경우 소폭의 희석 효과가 발생할 수 있습니다.

IDEAYA Biosciences (IDYA) a déposé un formulaire S-8 le 5 août 2025 pour enregistrer 2 000 000 d'actions ordinaires supplémentaires à émettre dans le cadre de son Plan de Récompenses d'Embauche 2023, portant le total des actions enregistrées pour ce plan à 4 millions. Ce plan, adopté et modifié par le conseil d'administration conformément à la règle Nasdaq 5635(c)(4) sans approbation des actionnaires, vise à attribuer des actions aux nouveaux employés. Le dépôt incorpore par référence le formulaire 10-K 2024, les formulaires 10-Q 2025 et les récents 8-K de la société, incluant les avis juridiques habituels et les consentements. Aucune donnée financière ni changement de stratégie d'entreprise n'est divulgué ; cette action est de nature administrative et pourrait entraîner une dilution modérée si toutes les actions sont émises.

IDEAYA Biosciences (IDYA) reichte am 5. August 2025 ein Formular S-8 ein, um zusätzlich 2.000.000 Stammaktien zur Ausgabe im Rahmen seines Employment Inducement Award Plans 2023 zu registrieren, wodurch die insgesamt für den Plan registrierten Aktien auf 4 Millionen steigen. Der Plan, der vom Vorstand gemäß Nasdaq-Regel 5635(c)(4) ohne Zustimmung der Aktionäre angenommen und geändert wurde, soll Aktienprämien an Neueinstellungen gewähren. Die Einreichung bezieht sich auf den 2024er Form 10-K, die 2025er Form 10-Qs und die aktuellen 8-Ks des Unternehmens und enthält die üblichen rechtlichen Gutachten und Zustimmungen. Es werden keine finanziellen Leistungsdaten oder Änderungen der Unternehmensstrategie offengelegt; die Maßnahme ist administrativ und kann bei vollständiger Ausgabe aller Aktien zu einer moderaten Verwässerung führen.

0001364885false00013648852025-08-052025-08-05


UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): August 5, 2025
 
Spirit AeroSystems Holdings, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware 001-33160 20-2436320
(State or other jurisdiction
of incorporation)
 (Commission
File Number)
 (I.R.S. Employer
Identification Number)
 
3801 South Oliver, Wichita, Kansas 67210
(Address of principal executive offices)(zip code)

(316526-9000
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Class A common stock, par value $0.01 per shareSPRNew York Stock Exchange




Item 2.02. Results of Operations and Financial Condition
 
On August 5, 2025, Spirit AeroSystems Holdings, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the six month period ended July 3, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
 
The information in Item 2.02, including the exhibit, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits

 (d) Exhibits
 
Furnished
 
Exhibit 99.1 — Press Release dated August 5, 2025

Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)







































2





SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 SPIRIT AEROSYSTEMS HOLDINGS, INC.
  
Date: August 5, 2025/s/ Irene M. Esteves
 Irene M. Esteves
 Executive Vice President and Chief Financial Officer

3

FAQ

Why did IDEAYA Biosciences (IDYA) file a Form S-8 on August 5, 2025?

To register 2,000,000 additional common shares for issuance under its 2023 Employment Inducement Award Plan.

How many total shares are now registered under IDYA’s Inducement Plan?

With this filing, the total available rises to 4,000,000 shares (2 M previously registered plus 2 M newly registered).

Does the plan require shareholder approval?

No. The board adopted and amended the plan under Nasdaq Rule 5635(c)(4), which exempts inducement grants from shareholder approval.

Will the Form S-8 impact IDEAYA’s earnings or cash position?

No financial statements are included. Registering shares is an administrative action and does not affect cash or earnings.

What exhibits are included with the S-8 filing?

Key exhibits include legal opinions (Ex. 5.1), auditor consent (Ex. 23.1), the amended Inducement Plan documents (Ex. 99 series) and the filing fee table (Ex. 107.1).
Spirit Aerosys

NYSE:SPR

SPR Rankings

SPR Latest News

SPR Latest SEC Filings

SPR Stock Data

4.61B
116.47M
0.69%
91.66%
8.61%
Aerospace & Defense
Aircraft Parts & Auxiliary Equipment, Nec
Link
United States
WICHITA